Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit ...

The success of obesity drug Mounjaro turned Eli Lilly into the first $1 trillion drugmaker on Friday, while Danish rival Novo ...

MONDAY, Nov. 24, 2025 (HealthDay News) — Eli Lilly reached a major milestone Friday, becoming the first healthcare company in ...

Evan Seigerman, BMO head of health care research, joins 'The Exchange' to discuss the gap between Novo Nordisk and Eli Lilly, ...

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

The market for GLP-1 medications is already huge, and is expected to explode. It was valued at about $52 billion in 2024; ...

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...

LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across ...

Eli Lilly and Company (NYSE: LLY) today announced that new data from across its breast oncology portfolio and pipeline will ...

Morgan Stanley raised the firm’s price target on Eli Lilly (LLY) to $1,290 from $1,171 and keeps an Overweight rating on the ...

Eli Lilly’s stock (NYSE: LLY) soared nearly 50%, driven not only by outstanding earnings and a notable margin increase, but ...

Just in time for the holiday season, Lilly unveiled its multi-pronged campaign to tie in Alzheimer’s awareness with cultural ...